These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11072027)

  • 1. Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia.
    Kabarowski JH; Witte ON
    Stem Cells; 2000; 18(6):399-408. PubMed ID: 11072027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia.
    Pierce A; Owen-Lynch PJ; Spooncer E; Dexter TM; Whetton AD
    Oncogene; 1998 Aug; 17(5):667-72. PubMed ID: 9704934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
    Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
    Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
    Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
    Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia.
    Møller GM; Frost V; Melo JV; Chantry A
    FEBS Lett; 2007 Apr; 581(7):1329-34. PubMed ID: 17349636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic stem cells in chronic myeloid leukemia.
    Petzer AL; Gunsilius E
    Arch Med Res; 2003; 34(6):496-506. PubMed ID: 14734089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells.
    Coppo P; Dusanter-Fourt I; Millot G; Nogueira MM; Dugray A; Bonnet ML; Mitjavila-Garcia MT; Le Pesteur D; Guilhot F; Vainchenker W; Sainteny F; Turhan AG
    Oncogene; 2003 Jun; 22(26):4102-10. PubMed ID: 12821944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
    Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
    Ly C; Arechiga AF; Melo JV; Walsh CM; Ong ST
    Cancer Res; 2003 Sep; 63(18):5716-22. PubMed ID: 14522890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model.
    Ren R
    Oncogene; 2002 Dec; 21(56):8629-42. PubMed ID: 12476309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
    Ren SY; Xue F; Feng J; Skorski T
    Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model mice for BCR/ABL-positive leukemias.
    Honda H; Hirai H
    Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biology of chronic myelogenous leukemia:mouse models and cell adhesion.
    Wertheim JA; Miller JP; Xu L; He Y; Pear WS
    Oncogene; 2002 Dec; 21(56):8612-28. PubMed ID: 12476308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myeloid leukaemia: stem cell derived but progenitor cell driven.
    Marley SB; Gordon MY
    Clin Sci (Lond); 2005 Jul; 109(1):13-25. PubMed ID: 15966868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
    Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
    Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of transformation by the BCR-ABL oncogene.
    Sattler M; Griffin JD
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):4-10. PubMed ID: 12783368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.